EICHORCondition: Advanced Degeneration of the Hip Joint · Revision of the Hip Joint · Sponsor: Smith & Nephew, Inc.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The purpose of this study is to assess the safety and effectiveness of the OR3O™ Dual Mobility System. The study will evaluate the outcome of the Total Hip Arthroplasty using the OR3O™ Dual Mobility System over a ten year period. Survivorship of THA will be assessed up to ten years.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Kentucky | Lexington, Kentucky, United States | — |
| University of Nebraska Medical Center | Omaha, Nebraska, United States | — |
| NYU Langone Health | New York, New York, United States | — |
| Hospital for Special Surgery | New York, New York, United States | — |
| Wake Forest School of Medicine | Winston-Salem, North Carolina, United States | — |
| St. David's Center for Hip and Knee Replacement | Austin, Texas, United States | — |
| Mater Health Services | Brisbane, Queensland, Australia | — |
| Royal Perth Hospital | Perth, Western Australia, Australia | — |
| Calvary John James Hospital | Deakin, Australia | — |
| South Health Campus, Calgary | Calgary, Alberta, Canada | — |
| St Michael's Hospital | Toronto, Ontario, Canada | — |
| Queen Mary Hospital | Hong Kong, Hong Kong | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04325022